Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
K NozawaM TeradaM OnishiY OzakiT TakanoW FakhouriD NovickJ M HaroL H FarisT KawaguchiY TanizawaJunji TsurutaniPublished in: Breast cancer (Tokyo, Japan) (2023)
In a routine clinical practice setting in Japan, patients with HR + , HER2- MBC appear to benefit from abemaciclib treatment in terms of treatment response and median PFS, with the results broadly reflecting the evidence demonstrated in clinical trials.